Integrated Biomarker Panel for Therapeutic Window Identification

Target: CHI3L1 Composite Score: 0.615 Price: $0.61 Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.615

Top 8% of 512 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

B+ Mech. Plausibility 15% 0.72 Top 46%

B Evidence Strength 15% 0.68 Top 42%

B Novelty 12% 0.65 Top 80%

B+ Feasibility 12% 0.78 Top 29%

B+ Impact 12% 0.70 Top 49%

A Druggability 10% 0.85 Top 24%

A Safety Profile 8% 0.80 Top 20%

B Competition 6% 0.60 Top 69%

B+ Data Availability 5% 0.75 Top 30%

B+ Reproducibility 5% 0.72 Top 30%

Evidence

4 supporting | 4 opposing

Citation quality: 0%

Debates

0 sessions

No debates yet

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

What are the precise temporal dynamics of astrocyte ketone production decline during neurodegeneration progression?

The debate identified a critical therapeutic window when astrocytic ketone production declines but neurons retain oxidation capacity, but the exact timing and molecular triggers remain undefined. This temporal characterization is essential for optimizing intervention timing across different neurodegenerative diseases. Source: Debate session sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd (Analysis: SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone Deficiency to Neuroinflammation

Score: 0.645 | Target: HCAR2

→ View full analysis & all 2 hypotheses

Description

Plasma CHI3L1/YKL-40 elevation combined with declining βHB defines the closing therapeutic window. The therapeutic window can be precisely identified using a biomarker panel combining: (1) rising plasma CHI3L1/YKL-40 (indicating astrocyte reactivity/inflammation), (2) declining plasma β-hydroxybutyrate (direct metabolic marker), and (3) stable neuronal biomarkers (NfL, tau) indicating preserved neuronal mass. This combination identifies the transition point when astrocyte support fails but neurons remain salvageable.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

8 citations 4 with PMID Validation: 0% 4 supporting / 4 opposing

Evidence Matrix — sortable by strength/year, click Abstract to expand

Claim	Type	Source	Strength ↕	Year ↕	PMIDs	Abstract
CHI3L1/YKL-40 signaling inhibits neurogenesis in A…	Supporting	-	-	-	PMID:40680137	-
CSF/blood biomarkers track neurodegeneration progr…	Supporting	-	-	-	PMID:34384464	-
Astrocyte reactivity correlates with metabolic dys…	Supporting	-	-	-	PMID:39201607	-
GFAP and YKL-40 mediate early AD progression	Supporting	-	-	-	PMID:37690071	-
Proposed cutoffs (CHI3L1 > 150 ng/mL + βHB <…	Opposing	-	-	-	-	-
Panel doesn't distinguish cause from effect; …	Opposing	-	-	-	-	-
NfL reflects axonal damage; by time NfL increases …	Opposing	-	-	-	-	-
Multiple biomarker panels have failed in AD clinic…	Opposing	-	-	-	-	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 4

CHI3L1/YKL-40 signaling inhibits neurogenesis in AD models

PMID:40680137

CSF/blood biomarkers track neurodegeneration progression

PMID:34384464

Astrocyte reactivity correlates with metabolic dysfunction

PMID:39201607

GFAP and YKL-40 mediate early AD progression

PMID:37690071

✗ Opposing Evidence 4

Proposed cutoffs (CHI3L1 > 150 ng/mL + βHB < 0.3 mM) lack validation studies

Panel doesn't distinguish cause from effect; identifies correlation not mechanism

NfL reflects axonal damage; by time NfL increases 80%, substantial neuronal loss may be irreversible

Multiple biomarker panels have failed in AD clinical translation

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

High

0.0877

Events (7d)

⚡ Price Movement Log Recent 3 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.610	▼ 8.4%	evidence_update	2026-04-15 20:24
📄	New Evidence	$0.666	▲ 9.2%	evidence_update	2026-04-15 20:24
✨	Listed	$0.610		post_process	2026-04-15 20:24